<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04718259</url>
  </required_header>
  <id_info>
    <org_study_id>Intrathecal midazolam</org_study_id>
    <nct_id>NCT04718259</nct_id>
  </id_info>
  <brief_title>The Use of Midazolam as Adjuvant to Bupivacaine Intrathecal Anesthesia for Children Undergoing Lower Abdominal Surgeries.</brief_title>
  <official_title>Evaluation of the Intraoperative and PO Analgesic Outcome of Using Midazolam as Adjuvant to Bupivacaine Intrathecal Anesthesia for Children Undergoing Lower Abdominal Surgeries.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be carried on children undergoing lower abdominal surgeries. Patients will be&#xD;
      randomly categorized into two study groups. Group A will include patients who will receive&#xD;
      bupivacaine intrathecal injection without adjuvant. Group B will include patients who will&#xD;
      receive bupivacaine and preservative-free midazolam.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 18, 2020</start_date>
  <completion_date type="Actual">March 10, 2021</completion_date>
  <primary_completion_date type="Actual">February 28, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of postoperative analgesia</measure>
    <time_frame>90 days</time_frame>
    <description>Efficacy of PO analgesia will be determined, by an assistant who will be blinded about the using the observational pain-discomfort scale (OPS), which assesses behavioral parameters that can be evaluated objectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of analgesia</measure>
    <time_frame>90 days</time_frame>
    <description>defined as the time elapsed since end of the surgical procedure till OPS reaches &gt;11</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post operative resolution of motor block</measure>
    <time_frame>90 days</time_frame>
    <description>will be assessed using Bromage score till complete recovery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The level of Post operative sedation</measure>
    <time_frame>90 days</time_frame>
    <description>will be assessed at 30 &amp; 120 minutes after admission to the recovery room using the modified WilsonSedation Score (WSS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PO hospital stay</measure>
    <time_frame>90 days</time_frame>
    <description>Duration of PO hospital stay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of procedural success</measure>
    <time_frame>90 days</time_frame>
    <description>Defined as peak sensory level at least T10, Bromage score at 3 at 10-min after spina block and no response to surgical stimuli once surgery will be allowed to start.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Analgesia</condition>
  <condition>Children, Only</condition>
  <condition>Bupivacaine</condition>
  <condition>Midazolam</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will include patients who will receive bupivacaine intrathecal injection without adjuvant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will include patients who will receive bupivacaine and midazolam.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intrathecal bupivacaine</intervention_name>
    <description>The use of intrathecal bupivacaine will be compared to the use of intrathecal bupivacaine and midazolam.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>intrathecal bupivacaine and midazolam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam</intervention_name>
    <description>midazolam</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All children aged 3-12 years, assigned for lower abdominal and pelvic surgeries and&#xD;
             will be ASA grade I after obtaining written fully informed parental consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with congenital anomalies especially of the spine, infections in the skin of&#xD;
             the back, had coagulopathy, or allergy to the study drugs and those whose parents&#xD;
             refused to give the consent .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alemeis hospital ksa</name>
      <address>
        <city>Jazan</city>
        <zip>00966</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>MOHAMMED FAWZI ALI ABOSAMAK</investigator_full_name>
    <investigator_title>consultant anesthesia</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>After analyzing the data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

